M707102

M707102 is an investigational small molecule drug candidate being developed by Maruho Co., Ltd. for the topical treatment of actinic keratosis (AK). Actinic keratosis is a precancerous skin condition caused by chronic exposure to ultraviolet radiation, which can progress to squamous cell carcinoma if left untreated. M707102 is currently in early-stage clinical development, with a Phase 1 first-in-human study initiated in Japan in 2023 to evaluate the safety, tolerability, and pharmacokinetics of a single topical application under occlusion in healthy male subjects. While the specific molecular target has not been publicly disclosed, the drug is being developed as a localized topical therapy to provide a non-invasive treatment option for AK lesions.